Search Results: Treatment + Breast Cancer (17 results)
Study of the drug TNG260 and an Immunotherapy in Advanced Solid Tumors With a STK11 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/333/study-of-the-drug-tng260-and-an-immunotherapy-in-advanced-solid-tumors-with-a-stk11-mutation
Treatment
This is a treatment study enrolling people with advanced or metastatic solid tumors with known STK11 mutations
The study is designed to find the safest dose of a drug called TNG260, given along with a standard dose of the immunotherapy drug pembrolizumab, in people with advanced or metastatic solid tumors and have a STK11 genetic mutation.
Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors
Treatment
Treatment study for people with advanced solid tumors
The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations.
Treating Advanced Cancers with BRCA or Other Related Gene Mutations Using Targeted Therapy MOMA-313 Alone or In Combination with the PARP Inhibitor Olaparib
https://www.facingourrisk.org/research-clinical-trials/study/328/treating-advanced-cancers-with-dna-repair-mutations-using-moma-313-alone-or-in-combination-with-the-parp-inhibitor-olaparib
Treatment
Treatment study for people with advanced or metastatic cancers
This trial will study the safety, tolerability, and initial effectiveness of MOMA-313, a new type of targeted therapy, alone or in combination with the PARP inhibitor olaparib to treat people with advanced or metastatic cancers with certain types of mutations.
Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation
Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor
This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.
Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation
https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation
Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation
This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas
Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/285/treatment-study-for-people-with-stage-2-or-3-triple-negative-breast-cancer-at-high-risk-for-recurrence
Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence
Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:
- For people diagnosed with stage 2 or stage 3 triple-negative breast cancer at high risk for recurrence.
- People with an inherited mutation in BRCA1, BRCA2, or PALB2 who are planning to undergo a risk-reducing mastectomy.
Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)
https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study
Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas
This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.
A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer
https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer
Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer
This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib
https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib
Treatment
Treatment study for people with advanced solid tumors
This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.
SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells
https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells
Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation
The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.
Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation
https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation
Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation
This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.
Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)
https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
Treatment
Advanced ovarian, breast, prostate or pancreatic cancer
PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.
Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors
https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors
Treatment
Advanced solid tumors
This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.
Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations
https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations
Treatment
This is a study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy
This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1and BRCA2 mutation to determine whether this treatment (which is already approved for germline BRCA1 and BRCA2 carriers) is effective in this population.
A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients
https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach
Treatment
A study looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home
Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home!
Additional Results on Clinicaltrials.gov Treatment + Breast Cancer
504 results
Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT ID: NCT04824027 (https://clinicaltrials.gov/study/NCT04824027)
Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function
NCT ID: NCT06081127 (https://clinicaltrials.gov/study/NCT06081127)
A Study of SGN-PDL1V in Advanced Solid Tumors
NCT ID: NCT05208762 (https://clinicaltrials.gov/study/NCT05208762)
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT ID: NCT05000294 (https://clinicaltrials.gov/study/NCT05000294)
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT ID: NCT04561362 (https://clinicaltrials.gov/study/NCT04561362)
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
NCT ID: NCT05932862 (https://clinicaltrials.gov/study/NCT05932862)
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://clinicaltrials.gov/study/NCT05483491)
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT ID: NCT05544929 (https://clinicaltrials.gov/study/NCT05544929)
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
NCT ID: NCT05766891 (https://clinicaltrials.gov/study/NCT05766891)
Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT ID: NCT04998682 (https://clinicaltrials.gov/study/NCT04998682)
Study of XB010 in Subjects With Solid Tumors
NCT ID: NCT06545331 (https://clinicaltrials.gov/study/NCT06545331)
Trial of Pre-operative Neratinib and Endocrine Therapy with Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT ID: NCT04886531 (https://clinicaltrials.gov/study/NCT04886531)
Ultrahypofractionation and Normal Tissue Toxicity
NCT ID: NCT05912231 (https://clinicaltrials.gov/study/NCT05912231)
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
NCT ID: NCT06172127 (https://clinicaltrials.gov/study/NCT06172127)
Breast Mesh Used in Two-staged Breast Reconstruction
NCT ID: NCT04967976 (https://clinicaltrials.gov/study/NCT04967976)
A Study of Breast Cancer Risk Factors and Outcomes of People in Florida
NCT ID: NCT06780176 (https://clinicaltrials.gov/study/NCT06780176)
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT ID: NCT06312176 (https://clinicaltrials.gov/study/NCT06312176)
Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer
NCT ID: NCT05422794 (https://clinicaltrials.gov/study/NCT05422794)
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer Patients (TOPAZ)
NCT ID: NCT05269160 (https://clinicaltrials.gov/study/NCT05269160)
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT ID: NCT05735080 (https://clinicaltrials.gov/study/NCT05735080)
Ribociclib and Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT ID: NCT05467891 (https://clinicaltrials.gov/study/NCT05467891)
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
NCT ID: NCT06252662 (https://clinicaltrials.gov/study/NCT06252662)
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT ID: NCT02977468 (https://clinicaltrials.gov/study/NCT02977468)
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT ID: NCT04648904 (https://clinicaltrials.gov/study/NCT04648904)
Study of 18F-FFNP Breast PET/MRI
NCT ID: NCT06086704 (https://clinicaltrials.gov/study/NCT06086704)
Researching the Effect of Exercise on Cancer
NCT ID: NCT04589468 (https://clinicaltrials.gov/study/NCT04589468)
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://clinicaltrials.gov/study/NCT05092373)
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
NCT ID: NCT05856773 (https://clinicaltrials.gov/study/NCT05856773)
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients
NCT ID: NCT05074290 (https://clinicaltrials.gov/study/NCT05074290)
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer
NCT ID: NCT05650879 (https://clinicaltrials.gov/study/NCT05650879)
Pre-analytical Factors Affecting CtDNA Analysis in Early and Locally Advanced Breast Cancer
NCT ID: NCT05945290 (https://clinicaltrials.gov/study/NCT05945290)
DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
NCT ID: NCT04567420 (https://clinicaltrials.gov/study/NCT04567420)
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
NCT ID: NCT06100874 (https://clinicaltrials.gov/study/NCT06100874)
Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NCT ID: NCT04959474 (https://clinicaltrials.gov/study/NCT04959474)
Ribociclib and Bicalutamide in AR+ TNBC
NCT ID: NCT03090165 (https://clinicaltrials.gov/study/NCT03090165)
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT ID: NCT06393374 (https://clinicaltrials.gov/study/NCT06393374)
Turkey Tail Mushroom for Treating Post-Menopausal Women With HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
NCT ID: NCT06450873 (https://clinicaltrials.gov/study/NCT06450873)
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
NCT ID: NCT05888831 (https://clinicaltrials.gov/study/NCT05888831)
A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
NCT ID: NCT06471673 (https://clinicaltrials.gov/study/NCT06471673)
Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
NCT ID: NCT05770531 (https://clinicaltrials.gov/study/NCT05770531)
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
NCT ID: NCT06545682 (https://clinicaltrials.gov/study/NCT06545682)
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
NCT ID: NCT06428682 (https://clinicaltrials.gov/study/NCT06428682)
A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://clinicaltrials.gov/study/NCT05107674)
Microbiome and Association With Implant Infections
NCT ID: NCT05020574 (https://clinicaltrials.gov/study/NCT05020574)
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT ID: NCT05458674 (https://clinicaltrials.gov/study/NCT05458674)
NearWave Optical Molecular Monitoring
NCT ID: NCT06744465 (https://clinicaltrials.gov/study/NCT06744465)
Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
NCT ID: NCT05579366 (https://clinicaltrials.gov/study/NCT05579366)
Focused Ultrasound and Gemcitabine in Breast Cancer
NCT ID: NCT04796220 (https://clinicaltrials.gov/study/NCT04796220)
Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT ID: NCT05941520 (https://clinicaltrials.gov/study/NCT05941520)
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT ID: NCT03572374 (https://clinicaltrials.gov/study/NCT03572374)
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT ID: NCT06188520 (https://clinicaltrials.gov/study/NCT06188520)
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://clinicaltrials.gov/study/NCT04771520)
Study of LP-184 in Patients with Advanced Solid Tumors
NCT ID: NCT05933265 (https://clinicaltrials.gov/study/NCT05933265)
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT ID: NCT05952557 (https://clinicaltrials.gov/study/NCT05952557)
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT ID: NCT04140526 (https://clinicaltrials.gov/study/NCT04140526)
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT ID: NCT04768426 (https://clinicaltrials.gov/study/NCT04768426)
PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT ID: NCT05868226 (https://clinicaltrials.gov/study/NCT05868226)
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT ID: NCT05319873 (https://clinicaltrials.gov/study/NCT05319873)
GammaPod Registry and Quality of Life Nomogram
NCT ID: NCT03562273 (https://clinicaltrials.gov/study/NCT03562273)
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT ID: NCT05464082 (https://clinicaltrials.gov/study/NCT05464082)
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT ID: NCT03909282 (https://clinicaltrials.gov/study/NCT03909282)
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT ID: NCT05563220 (https://clinicaltrials.gov/study/NCT05563220)
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
NCT ID: NCT06253520 (https://clinicaltrials.gov/study/NCT06253520)
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT ID: NCT05879926 (https://clinicaltrials.gov/study/NCT05879926)
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
NCT ID: NCT05756166 (https://clinicaltrials.gov/study/NCT05756166)
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
NCT ID: NCT05696626 (https://clinicaltrials.gov/study/NCT05696626)
Brodalumab in the Treatment of Immune-Related Adverse Events
NCT ID: NCT06673329 (https://clinicaltrials.gov/study/NCT06673329)
High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
NCT ID: NCT06538389 (https://clinicaltrials.gov/study/NCT06538389)
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT ID: NCT05705401 (https://clinicaltrials.gov/study/NCT05705401)
ETHAN - ET for Male BC
NCT ID: NCT05501704 (https://clinicaltrials.gov/study/NCT05501704)
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
NCT ID: NCT05593094 (https://clinicaltrials.gov/study/NCT05593094)
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
NCT ID: NCT06686394 (https://clinicaltrials.gov/study/NCT06686394)
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
NCT ID: NCT05645380 (https://clinicaltrials.gov/study/NCT05645380)
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT ID: NCT05313191 (https://clinicaltrials.gov/study/NCT05313191)
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
NCT ID: NCT04147494 (https://clinicaltrials.gov/study/NCT04147494)
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT ID: NCT05020860 (https://clinicaltrials.gov/study/NCT05020860)
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced Cancer
NCT ID: NCT05969860 (https://clinicaltrials.gov/study/NCT05969860)
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT ID: NCT04614194 (https://clinicaltrials.gov/study/NCT04614194)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://clinicaltrials.gov/study/NCT04550494)
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://clinicaltrials.gov/study/NCT05417594)
Vapocoolant Analgesia for Breast Lymphoscintigraphy
NCT ID: NCT05744557 (https://clinicaltrials.gov/study/NCT05744557)
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells with or Without Naxitamab (Danyelza) for the Treatment of Patients with Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://clinicaltrials.gov/study/NCT06026657)
Hippocampal Avoidance in Craniospinal Irradiation for the Treatment of Leptomeningeal Metastases From Breast Cancer or Non-small Cell Lung Cancer
NCT ID: NCT06518057 (https://clinicaltrials.gov/study/NCT06518057)
Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT ID: NCT06275126 (https://clinicaltrials.gov/study/NCT06275126)
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
NCT ID: NCT06130826 (https://clinicaltrials.gov/study/NCT06130826)
Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
NCT ID: NCT05573126 (https://clinicaltrials.gov/study/NCT05573126)
Trial of 225Ac-DOTATATE (RYZ101) in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
NCT ID: NCT06590857 (https://clinicaltrials.gov/study/NCT06590857)
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT ID: NCT05412225 (https://clinicaltrials.gov/study/NCT05412225)
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
NCT ID: NCT04606030 (https://clinicaltrials.gov/study/NCT04606030)
Self-Determination Theory-informed Occupational Therapy Program to Increase Physical Activity Among Survivors of Breast Cancer
NCT ID: NCT06671730 (https://clinicaltrials.gov/study/NCT06671730)
The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT ID: NCT05037825 (https://clinicaltrials.gov/study/NCT05037825)
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT ID: NCT05183126 (https://clinicaltrials.gov/study/NCT05183126)
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT ID: NCT06249048 (https://clinicaltrials.gov/study/NCT06249048)
Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
NCT ID: NCT05056857 (https://clinicaltrials.gov/study/NCT05056857)
TReatment of ADC-Refractory Breast CancEr with Dato-DXd or T-DXd: TRADE DXd
NCT ID: NCT06533826 (https://clinicaltrials.gov/study/NCT06533826)
BREAST Choice Decision Tool R21
NCT ID: NCT06817226 (https://clinicaltrials.gov/study/NCT06817226)
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
NCT ID: NCT03351348 (https://clinicaltrials.gov/study/NCT03351348)
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.
NCT ID: NCT05289466 (https://clinicaltrials.gov/study/NCT05289466)
SABER Study for Selected Early Stage Breast Cancer
NCT ID: NCT04360330 (https://clinicaltrials.gov/study/NCT04360330)
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT ID: NCT06065748 (https://clinicaltrials.gov/study/NCT06065748)
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://clinicaltrials.gov/study/NCT02632448)
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT ID: NCT06324357 (https://clinicaltrials.gov/study/NCT06324357)
Avelumab or Hydroxychloroquine with or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT ID: NCT04841148 (https://clinicaltrials.gov/study/NCT04841148)
Study of 3-Day Partial Breast Radiation Therapy in Women with Breast Cancer
NCT ID: NCT04084730 (https://clinicaltrials.gov/study/NCT04084730)
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT ID: NCT04039230 (https://clinicaltrials.gov/study/NCT04039230)
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
NCT ID: NCT03524430 (https://clinicaltrials.gov/study/NCT03524430)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://clinicaltrials.gov/study/NCT04673448)
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT ID: NCT05325866 (https://clinicaltrials.gov/study/NCT05325866)
Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery
NCT ID: NCT06297265 (https://clinicaltrials.gov/study/NCT06297265)
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://clinicaltrials.gov/study/NCT04329065)
InAdvance: Surveillance, Prevention, and Interception in a Population at Risk for Cancer
NCT ID: NCT05463796 (https://clinicaltrials.gov/study/NCT05463796)
Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study
NCT ID: NCT06584396 (https://clinicaltrials.gov/study/NCT06584396)
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
NCT ID: NCT06590558 (https://clinicaltrials.gov/study/NCT06590558)
Palbociclib and Pembrolizumab in Central Nervous System Metastases
NCT ID: NCT02896335 (https://clinicaltrials.gov/study/NCT02896335)
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT ID: NCT05864144 (https://clinicaltrials.gov/study/NCT05864144)
Outcomes and Cosmesis With Whole Breast Irradiation and Boost
NCT ID: NCT06295744 (https://clinicaltrials.gov/study/NCT06295744)
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT ID: NCT05372640 (https://clinicaltrials.gov/study/NCT05372640)
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT ID: NCT05218044 (https://clinicaltrials.gov/study/NCT05218044)
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT ID: NCT05537740 (https://clinicaltrials.gov/study/NCT05537740)
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT ID: NCT04009044 (https://clinicaltrials.gov/study/NCT04009044)
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://clinicaltrials.gov/study/NCT05887492)
Preoperative Irradiation for Stage I Breast Cancer
NCT ID: NCT05464667 (https://clinicaltrials.gov/study/NCT05464667)
Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients
NCT ID: NCT02772367 (https://clinicaltrials.gov/study/NCT02772367)
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
NCT ID: NCT00899301 (https://clinicaltrials.gov/study/NCT00899301)
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT ID: NCT06239467 (https://clinicaltrials.gov/study/NCT06239467)
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
NCT ID: NCT05703269 (https://clinicaltrials.gov/study/NCT05703269)
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
NCT ID: NCT06042569 (https://clinicaltrials.gov/study/NCT06042569)
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
NCT ID: NCT05892068 (https://clinicaltrials.gov/study/NCT05892068)
A Study of Pembrolizumab and Cryoablation in People with Breast Cancer
NCT ID: NCT06246968 (https://clinicaltrials.gov/study/NCT06246968)
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT ID: NCT06435429 (https://clinicaltrials.gov/study/NCT06435429)
Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://clinicaltrials.gov/study/NCT03804944)
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
NCT ID: NCT04703244 (https://clinicaltrials.gov/study/NCT04703244)
Cancer Genetic Testing in Ethnic Populations
NCT ID: NCT04475640 (https://clinicaltrials.gov/study/NCT04475640)
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)
National Cancer Institute "Cancer Moonshot Biobank"
NCT ID: NCT04314401 (https://clinicaltrials.gov/study/NCT04314401)
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT ID: NCT05130801 (https://clinicaltrials.gov/study/NCT05130801)
TRUDI: TDXD+Durva in HER2+/low IBC
NCT ID: NCT05795101 (https://clinicaltrials.gov/study/NCT05795101)
Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications
NCT ID: NCT05046301 (https://clinicaltrials.gov/study/NCT05046301)
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
NCT ID: NCT06099769 (https://clinicaltrials.gov/study/NCT06099769)
Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
NCT ID: NCT06408168 (https://clinicaltrials.gov/study/NCT06408168)
Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women
NCT ID: NCT05755269 (https://clinicaltrials.gov/study/NCT05755269)
Locally AblatiVe TherApy in OLigO-pRogressive SOlid TUmorS (VALOROUS)
NCT ID: NCT06103669 (https://clinicaltrials.gov/study/NCT06103669)
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
NCT ID: NCT06465368 (https://clinicaltrials.gov/study/NCT06465368)
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
NCT ID: NCT06027268 (https://clinicaltrials.gov/study/NCT06027268)
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
NCT ID: NCT05751668 (https://clinicaltrials.gov/study/NCT05751668)
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
NCT ID: NCT06568692 (https://clinicaltrials.gov/study/NCT06568692)
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT ID: NCT04282044 (https://clinicaltrials.gov/study/NCT04282044)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://clinicaltrials.gov/study/NCT05929768)
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
NCT ID: NCT06678269 (https://clinicaltrials.gov/study/NCT06678269)
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
NCT ID: NCT06444269 (https://clinicaltrials.gov/study/NCT06444269)
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://clinicaltrials.gov/study/NCT03671044)
Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer
NCT ID: NCT05417867 (https://clinicaltrials.gov/study/NCT05417867)
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer
NCT ID: NCT06361940 (https://clinicaltrials.gov/study/NCT06361940)
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients with Brain Metastases
NCT ID: NCT06764940 (https://clinicaltrials.gov/study/NCT06764940)
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT ID: NCT04862663 (https://clinicaltrials.gov/study/NCT04862663)
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT ID: NCT06428396 (https://clinicaltrials.gov/study/NCT06428396)
In Situ Immunomodulation with CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients W/ Unresectable and Metastatic Solid Tumors
NCT ID: NCT04616248 (https://clinicaltrials.gov/study/NCT04616248)
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT ID: NCT04443348 (https://clinicaltrials.gov/study/NCT04443348)
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT ID: NCT05693766 (https://clinicaltrials.gov/study/NCT05693766)
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://clinicaltrials.gov/study/NCT04644068)
Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
NCT ID: NCT06347068 (https://clinicaltrials.gov/study/NCT06347068)
A Registry Study of Breast Microseed Treatment
NCT ID: NCT02701244 (https://clinicaltrials.gov/study/NCT02701244)
IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients with Breast Cancer with Nodal Metastases
NCT ID: NCT06092892 (https://clinicaltrials.gov/study/NCT06092892)
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://clinicaltrials.gov/study/NCT04722692)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
NCT ID: NCT06157892 (https://clinicaltrials.gov/study/NCT06157892)
Metformin and Nightly Fasting in Women With Early Breast Cancer
NCT ID: NCT05023967 (https://clinicaltrials.gov/study/NCT05023967)
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT ID: NCT05736367 (https://clinicaltrials.gov/study/NCT05736367)
Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
NCT ID: NCT06559540 (https://clinicaltrials.gov/study/NCT06559540)
Intra-Operative Radiation Registry
NCT ID: NCT04994067 (https://clinicaltrials.gov/study/NCT04994067)
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT ID: NCT05607004 (https://clinicaltrials.gov/study/NCT05607004)
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03606967 (https://clinicaltrials.gov/study/NCT03606967)
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://clinicaltrials.gov/study/NCT05837767)
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://clinicaltrials.gov/study/NCT04090567)
The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients
NCT ID: NCT03270072 (https://clinicaltrials.gov/study/NCT03270072)
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT ID: NCT04265872 (https://clinicaltrials.gov/study/NCT04265872)
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)
Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)
NCT ID: NCT05472792 (https://clinicaltrials.gov/study/NCT05472792)
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
NCT ID: NCT05914792 (https://clinicaltrials.gov/study/NCT05914792)
A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.
NCT ID: NCT06247995 (https://clinicaltrials.gov/study/NCT06247995)
Estradiol Plus Olaparib for Breast Cancer (PHOEBE)
NCT ID: NCT05900895 (https://clinicaltrials.gov/study/NCT05900895)
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT ID: NCT04606446 (https://clinicaltrials.gov/study/NCT04606446)
Primary Breast Oligoprogressive Sites Treated with Radiotherapy to Obviate the Need to Change Systemic Therapy
NCT ID: NCT06055881 (https://clinicaltrials.gov/study/NCT06055881)
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor
NCT ID: NCT05933395 (https://clinicaltrials.gov/study/NCT05933395)
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT ID: NCT05245812 (https://clinicaltrials.gov/study/NCT05245812)
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT ID: NCT04891068 (https://clinicaltrials.gov/study/NCT04891068)
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases
NCT ID: NCT04647916 (https://clinicaltrials.gov/study/NCT04647916)
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
NCT ID: NCT05305924 (https://clinicaltrials.gov/study/NCT05305924)
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients
NCT ID: NCT05637216 (https://clinicaltrials.gov/study/NCT05637216)
Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
NCT ID: NCT04568616 (https://clinicaltrials.gov/study/NCT04568616)
Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
NCT ID: NCT04022616 (https://clinicaltrials.gov/study/NCT04022616)
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT ID: NCT05351424 (https://clinicaltrials.gov/study/NCT05351424)
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
NCT ID: NCT03589339 (https://clinicaltrials.gov/study/NCT03589339)
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT ID: NCT05894239 (https://clinicaltrials.gov/study/NCT05894239)
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Triple-negative Breast Cancer
NCT ID: NCT03546686 (https://clinicaltrials.gov/study/NCT03546686)
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT ID: NCT02476786 (https://clinicaltrials.gov/study/NCT02476786)
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer
NCT ID: NCT05226663 (https://clinicaltrials.gov/study/NCT05226663)
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
NCT ID: NCT06797635 (https://clinicaltrials.gov/study/NCT06797635)
Lymphedema Surveillance Study
NCT ID: NCT02743858 (https://clinicaltrials.gov/study/NCT02743858)
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
NCT ID: NCT03213041 (https://clinicaltrials.gov/study/NCT03213041)
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05785741 (https://clinicaltrials.gov/study/NCT05785741)
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
NCT ID: NCT02830724 (https://clinicaltrials.gov/study/NCT02830724)
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
NCT ID: NCT04119024 (https://clinicaltrials.gov/study/NCT04119024)
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT ID: NCT05501886 (https://clinicaltrials.gov/study/NCT05501886)
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT ID: NCT05768139 (https://clinicaltrials.gov/study/NCT05768139)
Study of Tucatinib and Doxil in Participants with Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
NCT ID: NCT05748834 (https://clinicaltrials.gov/study/NCT05748834)
Diabetes Care for Breast Cancer Patients
NCT ID: NCT05565534 (https://clinicaltrials.gov/study/NCT05565534)
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT ID: NCT03990896 (https://clinicaltrials.gov/study/NCT03990896)
A Tear-based, Lab-developed Test for Breast Cancer for Women With Dense Breast Tissue
NCT ID: NCT05268224 (https://clinicaltrials.gov/study/NCT05268224)
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer
NCT ID: NCT02290834 (https://clinicaltrials.gov/study/NCT02290834)
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT ID: NCT04677816 (https://clinicaltrials.gov/study/NCT04677816)
A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
NCT ID: NCT05142358 (https://clinicaltrials.gov/study/NCT05142358)
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer
NCT ID: NCT06315296 (https://clinicaltrials.gov/study/NCT06315296)
Losartan in Prevention of Radiation-Induced Heart Failure
NCT ID: NCT05607017 (https://clinicaltrials.gov/study/NCT05607017)
Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer
NCT ID: NCT06219434 (https://clinicaltrials.gov/study/NCT06219434)
NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
NCT ID: NCT05837455 (https://clinicaltrials.gov/study/NCT05837455)
Reiki Breast Surgery QOL Project for Women Undergoing Breast Surgery
NCT ID: NCT06524895 (https://clinicaltrials.gov/study/NCT06524895)
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
NCT ID: NCT05251714 (https://clinicaltrials.gov/study/NCT05251714)
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors
NCT ID: NCT05082610 (https://clinicaltrials.gov/study/NCT05082610)
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
NCT ID: NCT04389281 (https://clinicaltrials.gov/study/NCT04389281)
Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
NCT ID: NCT04175210 (https://clinicaltrials.gov/study/NCT04175210)
Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial
NCT ID: NCT06617455 (https://clinicaltrials.gov/study/NCT06617455)
Letrozole with and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT05464810 (https://clinicaltrials.gov/study/NCT05464810)
Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial
NCT ID: NCT06671912 (https://clinicaltrials.gov/study/NCT06671912)
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
NCT ID: NCT05098210 (https://clinicaltrials.gov/study/NCT05098210)
Refining Local-Regional Therapy for IBC
NCT ID: NCT04636710 (https://clinicaltrials.gov/study/NCT04636710)
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT ID: NCT06072612 (https://clinicaltrials.gov/study/NCT06072612)
Roll-over Study to Allow Continued Access to Ribociclib
NCT ID: NCT05161195 (https://clinicaltrials.gov/study/NCT05161195)
Niraparib + Dostarlimab in BRCA Mutated Breast Cancer
NCT ID: NCT04584255 (https://clinicaltrials.gov/study/NCT04584255)
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT ID: NCT06500455 (https://clinicaltrials.gov/study/NCT06500455)
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib
NCT ID: NCT05323955 (https://clinicaltrials.gov/study/NCT05323955)
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities
NCT ID: NCT06058650 (https://clinicaltrials.gov/study/NCT06058650)
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
NCT ID: NCT06500481 (https://clinicaltrials.gov/study/NCT06500481)
A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation
NCT ID: NCT06772181 (https://clinicaltrials.gov/study/NCT06772181)
Sexual Health in Breast Cancer Patients
NCT ID: NCT05138510 (https://clinicaltrials.gov/study/NCT05138510)
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer
NCT ID: NCT03979508 (https://clinicaltrials.gov/study/NCT03979508)
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
NCT ID: NCT04144023 (https://clinicaltrials.gov/study/NCT04144023)
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NCT ID: NCT05230810 (https://clinicaltrials.gov/study/NCT05230810)
Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision
NCT ID: NCT06572410 (https://clinicaltrials.gov/study/NCT06572410)
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
NCT ID: NCT05269381 (https://clinicaltrials.gov/study/NCT05269381)
Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis
NCT ID: NCT02735746 (https://clinicaltrials.gov/study/NCT02735746)
Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
NCT ID: NCT04799535 (https://clinicaltrials.gov/study/NCT04799535)
Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity
NCT ID: NCT04044872 (https://clinicaltrials.gov/study/NCT04044872)
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane
NCT ID: NCT03930680 (https://clinicaltrials.gov/study/NCT03930680)
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
NCT ID: NCT05076760 (https://clinicaltrials.gov/study/NCT05076760)
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NCT ID: NCT04756765 (https://clinicaltrials.gov/study/NCT04756765)
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT ID: NCT02926729 (https://clinicaltrials.gov/study/NCT02926729)
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT ID: NCT06245889 (https://clinicaltrials.gov/study/NCT06245889)
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT ID: NCT06022029 (https://clinicaltrials.gov/study/NCT06022029)
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
NCT ID: NCT06507618 (https://clinicaltrials.gov/study/NCT06507618)
Prevention of Frailty with Fisetin and Exercise (PROFFi) in Breast Cancer Survivors
NCT ID: NCT06113016 (https://clinicaltrials.gov/study/NCT06113016)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT ID: NCT06492616 (https://clinicaltrials.gov/study/NCT06492616)
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT ID: NCT04711824 (https://clinicaltrials.gov/study/NCT04711824)
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT ID: NCT04234386 (https://clinicaltrials.gov/study/NCT04234386)
Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)
NCT ID: NCT06246786 (https://clinicaltrials.gov/study/NCT06246786)
Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT ID: NCT05238922 (https://clinicaltrials.gov/study/NCT05238922)
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
NCT ID: NCT05553522 (https://clinicaltrials.gov/study/NCT05553522)
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT ID: NCT06449222 (https://clinicaltrials.gov/study/NCT06449222)
DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
NCT ID: NCT06388122 (https://clinicaltrials.gov/study/NCT06388122)
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
NCT ID: NCT03096418 (https://clinicaltrials.gov/study/NCT03096418)
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study
NCT ID: NCT04993313 (https://clinicaltrials.gov/study/NCT04993313)
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
NCT ID: NCT04222413 (https://clinicaltrials.gov/study/NCT04222413)
Study Evaluating Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients w/ Locally Advanced or Metastatic HR+/HER2- Breast Cancer
NCT ID: NCT04851613 (https://clinicaltrials.gov/study/NCT04851613)
A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)
NCT ID: NCT05035836 (https://clinicaltrials.gov/study/NCT05035836)
T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT ID: NCT04457596 (https://clinicaltrials.gov/study/NCT04457596)
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer
NCT ID: NCT04906395 (https://clinicaltrials.gov/study/NCT04906395)
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
NCT ID: NCT05219695 (https://clinicaltrials.gov/study/NCT05219695)
Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications
NCT ID: NCT05827614 (https://clinicaltrials.gov/study/NCT05827614)
Perioperative Mindfulness Proposal
NCT ID: NCT04049214 (https://clinicaltrials.gov/study/NCT04049214)
Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS)
NCT ID: NCT03513614 (https://clinicaltrials.gov/study/NCT03513614)
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer
NCT ID: NCT06220214 (https://clinicaltrials.gov/study/NCT06220214)
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
NCT ID: NCT04762979 (https://clinicaltrials.gov/study/NCT04762979)
3D Printed Breast Models in the Surgical Management of Breast Cancer
NCT ID: NCT05755984 (https://clinicaltrials.gov/study/NCT05755984)
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer
NCT ID: NCT05633979 (https://clinicaltrials.gov/study/NCT05633979)
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
NCT ID: NCT02945579 (https://clinicaltrials.gov/study/NCT02945579)
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://clinicaltrials.gov/study/NCT04899908)
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
NCT ID: NCT04003038 (https://clinicaltrials.gov/study/NCT04003038)
ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT ID: NCT06328738 (https://clinicaltrials.gov/study/NCT06328738)
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
NCT ID: NCT03987555 (https://clinicaltrials.gov/study/NCT03987555)
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
NCT ID: NCT06184750 (https://clinicaltrials.gov/study/NCT06184750)
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
NCT ID: NCT01042379 (https://clinicaltrials.gov/study/NCT01042379)
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT ID: NCT05870579 (https://clinicaltrials.gov/study/NCT05870579)
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery
NCT ID: NCT06127979 (https://clinicaltrials.gov/study/NCT06127979)
Preoperative Nicotine Cessation for Women With Breast Cancer Recommended for Reconstruction
NCT ID: NCT06461650 (https://clinicaltrials.gov/study/NCT06461650)
EMBRACE: Exercising Together
NCT ID: NCT06049355 (https://clinicaltrials.gov/study/NCT06049355)
The Evaluation of PC14586 in Patients with Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://clinicaltrials.gov/study/NCT04585750)
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
NCT ID: NCT05708950 (https://clinicaltrials.gov/study/NCT05708950)
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
NCT ID: NCT02422641 (https://clinicaltrials.gov/study/NCT02422641)
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER)
NCT ID: NCT04333706 (https://clinicaltrials.gov/study/NCT04333706)
Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors
NCT ID: NCT05590949 (https://clinicaltrials.gov/study/NCT05590949)
Adjuvant Therapy with an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer
NCT ID: NCT04674306 (https://clinicaltrials.gov/study/NCT04674306)
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy
NCT ID: NCT04266249 (https://clinicaltrials.gov/study/NCT04266249)
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
NCT ID: NCT06270706 (https://clinicaltrials.gov/study/NCT06270706)
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer
NCT ID: NCT04115306 (https://clinicaltrials.gov/study/NCT04115306)
Enhanced Assistance During Radiotherapy for Unmet Essential Needs
NCT ID: NCT06582849 (https://clinicaltrials.gov/study/NCT06582849)
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study
NCT ID: NCT04371913 (https://clinicaltrials.gov/study/NCT04371913)
TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers
NCT ID: NCT04485013 (https://clinicaltrials.gov/study/NCT04485013)
Definitive Radiation for High-Risk Spine Metastases
NCT ID: NCT06165419 (https://clinicaltrials.gov/study/NCT06165419)
Robotic vs. Open NSM for Early Stage Breast Cancer
NCT ID: NCT05720039 (https://clinicaltrials.gov/study/NCT05720039)
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
NCT ID: NCT05340673 (https://clinicaltrials.gov/study/NCT05340673)
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer
NCT ID: NCT06637306 (https://clinicaltrials.gov/study/NCT06637306)
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
NCT ID: NCT04557449 (https://clinicaltrials.gov/study/NCT04557449)
Phase 1b Combo w/ Ribociclib, Alpelisib, or Everolimus
NCT ID: NCT05508906 (https://clinicaltrials.gov/study/NCT05508906)
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy
NCT ID: NCT06006806 (https://clinicaltrials.gov/study/NCT06006806)
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced And/or Metastatic Breast Cancer
NCT ID: NCT06515470 (https://clinicaltrials.gov/study/NCT06515470)
A Study of Tetrathiomolybdate (TM) Plus Capecitabine
NCT ID: NCT06134375 (https://clinicaltrials.gov/study/NCT06134375)
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
NCT ID: NCT04923542 (https://clinicaltrials.gov/study/NCT04923542)
Trastuzumab Deruxtecan Alone or in Combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
NCT ID: NCT04553770 (https://clinicaltrials.gov/study/NCT04553770)
Dose Escalation and Expansion of BBO-10203 in Advanced Solid Tumors (BREAKER-101)
NCT ID: NCT06625775 (https://clinicaltrials.gov/study/NCT06625775)
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
NCT ID: NCT05824975 (https://clinicaltrials.gov/study/NCT05824975)
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT ID: NCT06545942 (https://clinicaltrials.gov/study/NCT06545942)
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
NCT ID: NCT06085742 (https://clinicaltrials.gov/study/NCT06085742)
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, As a Single Agent in Advanced Solid Tumor Patients and in Combination with Fulvestrant in Patients with Advanced Breast Cancer
NCT ID: NCT05216432 (https://clinicaltrials.gov/study/NCT05216432)
Core Biopsies for Establishing a Breast Tumor Tissue Repository
NCT ID: NCT02250352 (https://clinicaltrials.gov/study/NCT02250352)
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer
NCT ID: NCT04174352 (https://clinicaltrials.gov/study/NCT04174352)
A Study of SGN-B6A in Advanced Solid Tumors
NCT ID: NCT04389632 (https://clinicaltrials.gov/study/NCT04389632)
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer
NCT ID: NCT05150652 (https://clinicaltrials.gov/study/NCT05150652)
A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors
NCT ID: NCT06273852 (https://clinicaltrials.gov/study/NCT06273852)
Predicting Chronic Pain Following Breast Surgery
NCT ID: NCT04967352 (https://clinicaltrials.gov/study/NCT04967352)
Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients with Breast Cancer Undergoing Breast Surgery
NCT ID: NCT04169542 (https://clinicaltrials.gov/study/NCT04169542)
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
NCT ID: NCT04787042 (https://clinicaltrials.gov/study/NCT04787042)
Tablet-based Mobile Health Ultrasound for Point-of-care Breast Cancer Diagnosis in Nigeria (Mobile Health: Technology and Outcomes in Low and Middle-Income Countries)
NCT ID: NCT05561842 (https://clinicaltrials.gov/study/NCT05561842)
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
NCT ID: NCT04150042 (https://clinicaltrials.gov/study/NCT04150042)
Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis
NCT ID: NCT06374459 (https://clinicaltrials.gov/study/NCT06374459)
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
NCT ID: NCT06238921 (https://clinicaltrials.gov/study/NCT06238921)
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure with Breast Cancer
NCT ID: NCT05507879 (https://clinicaltrials.gov/study/NCT05507879)
Breast Cancer Survivorship Biorepository
NCT ID: NCT05786664 (https://clinicaltrials.gov/study/NCT05786664)
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
NCT ID: NCT01174121 (https://clinicaltrials.gov/study/NCT01174121)
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer
NCT ID: NCT05949021 (https://clinicaltrials.gov/study/NCT05949021)
Phase II Single Arm Trial of Low Dose Capecitabine in Patients with Advanced Breast Cancer
NCT ID: NCT06105684 (https://clinicaltrials.gov/study/NCT06105684)
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
NCT ID: NCT04990921 (https://clinicaltrials.gov/study/NCT04990921)
Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer
NCT ID: NCT06833502 (https://clinicaltrials.gov/study/NCT06833502)
A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer
NCT ID: NCT06327490 (https://clinicaltrials.gov/study/NCT06327490)
A Vaccine (MV-s-NAP) for the Treatment of Patients with Invasive Metastatic Breast Cancer
NCT ID: NCT04521764 (https://clinicaltrials.gov/study/NCT04521764)
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
NCT ID: NCT05378464 (https://clinicaltrials.gov/study/NCT05378464)
Trial of Neratinib Plus Capecitabine in Subjects with HER2-Negative Metastatic Breast Cancer with Brain Metastases and Abnormally Active HER2 Signaling
NCT ID: NCT04965064 (https://clinicaltrials.gov/study/NCT04965064)
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)
NCT ID: NCT05592938 (https://clinicaltrials.gov/study/NCT05592938)
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma in Situ
NCT ID: NCT06218303 (https://clinicaltrials.gov/study/NCT06218303)
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
NCT ID: NCT05069038 (https://clinicaltrials.gov/study/NCT05069038)
Cryoablation vs Lumpectomy in T1 Breast Cancers
NCT ID: NCT05505643 (https://clinicaltrials.gov/study/NCT05505643)
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
NCT ID: NCT03449238 (https://clinicaltrials.gov/study/NCT03449238)
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
NCT ID: NCT05741164 (https://clinicaltrials.gov/study/NCT05741164)
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT ID: NCT05826964 (https://clinicaltrials.gov/study/NCT05826964)
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
NCT ID: NCT05524584 (https://clinicaltrials.gov/study/NCT05524584)
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT ID: NCT04373564 (https://clinicaltrials.gov/study/NCT04373564)
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
NCT ID: NCT06144164 (https://clinicaltrials.gov/study/NCT06144164)
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
NCT ID: NCT06257264 (https://clinicaltrials.gov/study/NCT06257264)
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients
NCT ID: NCT02095184 (https://clinicaltrials.gov/study/NCT02095184)
CONFIRM: Magnetic Resonance Guided Radiation Therapy
NCT ID: NCT04368702 (https://clinicaltrials.gov/study/NCT04368702)
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients with Triple Negative Breast Cancer
NCT ID: NCT05677802 (https://clinicaltrials.gov/study/NCT05677802)
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
NCT ID: NCT06179303 (https://clinicaltrials.gov/study/NCT06179303)
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients
NCT ID: NCT05972343 (https://clinicaltrials.gov/study/NCT05972343)
Evaluation of Improved Onboard Patient Imaging
NCT ID: NCT06187103 (https://clinicaltrials.gov/study/NCT06187103)
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
NCT ID: NCT02276443 (https://clinicaltrials.gov/study/NCT02276443)
The Immune System's Response to Young Women's Breast Cancer
NCT ID: NCT01503190 (https://clinicaltrials.gov/study/NCT01503190)
Efficacy Verification in Early Diagnosis and Management of Lymphedema Through Home Body Water Analyzer
NCT ID: NCT06580743 (https://clinicaltrials.gov/study/NCT06580743)
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer
NCT ID: NCT05534438 (https://clinicaltrials.gov/study/NCT05534438)
BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer
NCT ID: NCT06441890 (https://clinicaltrials.gov/study/NCT06441890)
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
NCT ID: NCT06409390 (https://clinicaltrials.gov/study/NCT06409390)
Immune Response to Anti-HER2 Therapies in Patients with HER2-Positive Stage I-IV Breast Cancer
NCT ID: NCT04517838 (https://clinicaltrials.gov/study/NCT04517838)
Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers
NCT ID: NCT05919108 (https://clinicaltrials.gov/study/NCT05919108)
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
NCT ID: NCT06103864 (https://clinicaltrials.gov/study/NCT06103864)
De-convoluting Interactions Between Genes, the Cancer Environment, and the Immune System to Develop Therapies That Work for You
NCT ID: NCT05134779 (https://clinicaltrials.gov/study/NCT05134779)
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial
NCT ID: NCT03011684 (https://clinicaltrials.gov/study/NCT03011684)
Scalp Cooling in MBC
NCT ID: NCT04986579 (https://clinicaltrials.gov/study/NCT04986579)
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT ID: NCT06112379 (https://clinicaltrials.gov/study/NCT06112379)
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
NCT ID: NCT06750484 (https://clinicaltrials.gov/study/NCT06750484)
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)
NCT ID: NCT05675579 (https://clinicaltrials.gov/study/NCT05675579)
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer
NCT ID: NCT04683679 (https://clinicaltrials.gov/study/NCT04683679)
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in MTNBC
NCT ID: NCT06351332 (https://clinicaltrials.gov/study/NCT06351332)
Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)
NCT ID: NCT04985032 (https://clinicaltrials.gov/study/NCT04985032)
Temporal Immunologic Changes With Hypofractionated Radiation-Induced DNA Damage in Breast Cancer
NCT ID: NCT05406232 (https://clinicaltrials.gov/study/NCT05406232)
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
NCT ID: NCT05029999 (https://clinicaltrials.gov/study/NCT05029999)
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
NCT ID: NCT05898399 (https://clinicaltrials.gov/study/NCT05898399)
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors
NCT ID: NCT05595499 (https://clinicaltrials.gov/study/NCT05595499)
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
NCT ID: NCT01185132 (https://clinicaltrials.gov/study/NCT01185132)
Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer
NCT ID: NCT04397185 (https://clinicaltrials.gov/study/NCT04397185)
Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study
NCT ID: NCT05703399 (https://clinicaltrials.gov/study/NCT05703399)
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
NCT ID: NCT05787587 (https://clinicaltrials.gov/study/NCT05787587)
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
NCT ID: NCT04315233 (https://clinicaltrials.gov/study/NCT04315233)
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
NCT ID: NCT04197687 (https://clinicaltrials.gov/study/NCT04197687)
Comparison of the Breast Tumor Microenvironment
NCT ID: NCT03165487 (https://clinicaltrials.gov/study/NCT03165487)
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
NCT ID: NCT06760637 (https://clinicaltrials.gov/study/NCT06760637)
Study to Evaluate CCS1477 in Advanced Tumours
NCT ID: NCT03568656 (https://clinicaltrials.gov/study/NCT03568656)
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
NCT ID: NCT04895709 (https://clinicaltrials.gov/study/NCT04895709)
NAVAH Impact on Radiation Therapy Completion in Black Breast & Prostate Cancer Patients
NCT ID: NCT05978232 (https://clinicaltrials.gov/study/NCT05978232)
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT ID: NCT06756932 (https://clinicaltrials.gov/study/NCT06756932)
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab
NCT ID: NCT05325632 (https://clinicaltrials.gov/study/NCT05325632)
Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer
NCT ID: NCT04603209 (https://clinicaltrials.gov/study/NCT04603209)
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer
NCT ID: NCT05996107 (https://clinicaltrials.gov/study/NCT05996107)
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT ID: NCT05207709 (https://clinicaltrials.gov/study/NCT05207709)
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
NCT ID: NCT05035407 (https://clinicaltrials.gov/study/NCT05035407)
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
NCT ID: NCT05095207 (https://clinicaltrials.gov/study/NCT05095207)
ATEMPT 2.0: Adjuvant T-DM1 Vs TH
NCT ID: NCT04893109 (https://clinicaltrials.gov/study/NCT04893109)
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer
NCT ID: NCT03694756 (https://clinicaltrials.gov/study/NCT03694756)
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
NCT ID: NCT04300556 (https://clinicaltrials.gov/study/NCT04300556)
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients Patients
NCT ID: NCT05585788 (https://clinicaltrials.gov/study/NCT05585788)
Magnetic Resonance Imaging in Radiotherapy for Breast Cancer
NCT ID: NCT05902507 (https://clinicaltrials.gov/study/NCT05902507)
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT ID: NCT05812807 (https://clinicaltrials.gov/study/NCT05812807)
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
NCT ID: NCT05374915 (https://clinicaltrials.gov/study/NCT05374915)
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
NCT ID: NCT05768932 (https://clinicaltrials.gov/study/NCT05768932)
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT ID: NCT06018337 (https://clinicaltrials.gov/study/NCT06018337)
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
NCT ID: NCT06260332 (https://clinicaltrials.gov/study/NCT06260332)
Study of ORIC-114 in Patients with Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
NCT ID: NCT05315700 (https://clinicaltrials.gov/study/NCT05315700)
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
NCT ID: NCT03796559 (https://clinicaltrials.gov/study/NCT03796559)
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05382299 (https://clinicaltrials.gov/study/NCT05382299)
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
NCT ID: NCT03971409 (https://clinicaltrials.gov/study/NCT03971409)
Olaparib in Combination with Vorinostat in Patients with Relapsed/Refractory And/or Metastatic Breast Cancer
NCT ID: NCT03742245 (https://clinicaltrials.gov/study/NCT03742245)
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
NCT ID: NCT06129747 (https://clinicaltrials.gov/study/NCT06129747)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
NCT ID: NCT03412877 (https://clinicaltrials.gov/study/NCT03412877)
Postoperative Opt-In Narcotics Treatment in Breast
NCT ID: NCT05078398 (https://clinicaltrials.gov/study/NCT05078398)
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT ID: NCT06380751 (https://clinicaltrials.gov/study/NCT06380751)
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer
NCT ID: NCT05288777 (https://clinicaltrials.gov/study/NCT05288777)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT ID: NCT05564377 (https://clinicaltrials.gov/study/NCT05564377)
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
NCT ID: NCT05765851 (https://clinicaltrials.gov/study/NCT05765851)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://clinicaltrials.gov/study/NCT05277051)
Study of AVZO-021 in Patients With Advanced Solid Tumors
NCT ID: NCT05867251 (https://clinicaltrials.gov/study/NCT05867251)
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
NCT ID: NCT04348747 (https://clinicaltrials.gov/study/NCT04348747)
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT ID: NCT05950945 (https://clinicaltrials.gov/study/NCT05950945)
Positron Emission Tomography (PET) Imaging with Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness
NCT ID: NCT03321045 (https://clinicaltrials.gov/study/NCT03321045)
Feasibility Study of CBCT for IGRT in Cancer Patients
NCT ID: NCT06681233 (https://clinicaltrials.gov/study/NCT06681233)
Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer
NCT ID: NCT06260033 (https://clinicaltrials.gov/study/NCT06260033)
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
NCT ID: NCT05528133 (https://clinicaltrials.gov/study/NCT05528133)
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer
NCT ID: NCT05557877 (https://clinicaltrials.gov/study/NCT05557877)
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/NSABP B-63)
NCT ID: NCT05633654 (https://clinicaltrials.gov/study/NCT05633654)
Interpretations and Predictions of Patient Reported Outcomes by Breast Cancer Patients
NCT ID: NCT05064098 (https://clinicaltrials.gov/study/NCT05064098)
The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema
NCT ID: NCT05890677 (https://clinicaltrials.gov/study/NCT05890677)
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
NCT ID: NCT05774951 (https://clinicaltrials.gov/study/NCT05774951)
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer
NCT ID: NCT05514054 (https://clinicaltrials.gov/study/NCT05514054)
Long-term Safety of Nipple Sparing Mastectomy in Women With GPV in Breast Cancer
NCT ID: NCT06888388 (https://clinicaltrials.gov/study/NCT06888388)
Trial of PreoperAtive Radiation (TOPAz): a Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy with Immediate Autologous Breast Reconstruction with Integrated Nanomechanical Biomarker Evaluation
NCT ID: NCT05774678 (https://clinicaltrials.gov/study/NCT05774678)
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT ID: NCT06253871 (https://clinicaltrials.gov/study/NCT06253871)
VS-6766+Abema+Fulv in Met HR+/HER- BC
NCT ID: NCT05608252 (https://clinicaltrials.gov/study/NCT05608252)
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
NCT ID: NCT03941756 (https://clinicaltrials.gov/study/NCT03941756)
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
NCT ID: NCT06139107 (https://clinicaltrials.gov/study/NCT06139107)
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
NCT ID: NCT04837209 (https://clinicaltrials.gov/study/NCT04837209)
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences
NCT ID: NCT04650256 (https://clinicaltrials.gov/study/NCT04650256)
A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies
NCT ID: NCT05081609 (https://clinicaltrials.gov/study/NCT05081609)
Sacituzumab Govitecan In TNBC
NCT ID: NCT04230109 (https://clinicaltrials.gov/study/NCT04230109)
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
NCT ID: NCT03604315 (https://clinicaltrials.gov/study/NCT03604315)
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease
NCT ID: NCT03808337 (https://clinicaltrials.gov/study/NCT03808337)
Food for Thought - a Nutrition Intervention for Women Undergoing Active Treatment for Triple Negative Breast Cancer
NCT ID: NCT06582615 (https://clinicaltrials.gov/study/NCT06582615)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
NCT ID: NCT04802759 (https://clinicaltrials.gov/study/NCT04802759)
Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study
NCT ID: NCT05053152 (https://clinicaltrials.gov/study/NCT05053152)
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
NCT ID: NCT06377852 (https://clinicaltrials.gov/study/NCT06377852)
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05673200 (https://clinicaltrials.gov/study/NCT05673200)
Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer
NCT ID: NCT06488378 (https://clinicaltrials.gov/study/NCT06488378)
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction
NCT ID: NCT05190978 (https://clinicaltrials.gov/study/NCT05190978)
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis
NCT ID: NCT05376878 (https://clinicaltrials.gov/study/NCT05376878)
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
NCT ID: NCT04180371 (https://clinicaltrials.gov/study/NCT04180371)
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies
NCT ID: NCT05226871 (https://clinicaltrials.gov/study/NCT05226871)
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT ID: NCT03936478 (https://clinicaltrials.gov/study/NCT03936478)
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
NCT ID: NCT06439693 (https://clinicaltrials.gov/study/NCT06439693)
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)
NCT ID: NCT04427293 (https://clinicaltrials.gov/study/NCT04427293)
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT06460298 (https://clinicaltrials.gov/study/NCT06460298)
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT ID: NCT05891171 (https://clinicaltrials.gov/study/NCT05891171)
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System
NCT ID: NCT05291507 (https://clinicaltrials.gov/study/NCT05291507)
Combined Immunotherapies in Metastatic ER+ Breast Cancer
NCT ID: NCT04563507 (https://clinicaltrials.gov/study/NCT04563507)
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
NCT ID: NCT03424005 (https://clinicaltrials.gov/study/NCT03424005)
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
NCT ID: NCT04075305 (https://clinicaltrials.gov/study/NCT04075305)
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction
NCT ID: NCT03934905 (https://clinicaltrials.gov/study/NCT03934905)
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials
NCT ID: NCT05146297 (https://clinicaltrials.gov/study/NCT05146297)
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer
NCT ID: NCT06318897 (https://clinicaltrials.gov/study/NCT06318897)
3D Ultrasound for the Imaging of Lymph Nodes in Patients with Breast Cancer
NCT ID: NCT05704283 (https://clinicaltrials.gov/study/NCT05704283)
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
NCT ID: NCT03536897 (https://clinicaltrials.gov/study/NCT03536897)
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
NCT ID: NCT01766297 (https://clinicaltrials.gov/study/NCT01766297)
Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients
NCT ID: NCT06353997 (https://clinicaltrials.gov/study/NCT06353997)
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment
NCT ID: NCT02807597 (https://clinicaltrials.gov/study/NCT02807597)
Vaccination With Flt3L, Radiation, and Poly-ICLC
NCT ID: NCT03789097 (https://clinicaltrials.gov/study/NCT03789097)
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial
NCT ID: NCT05710328 (https://clinicaltrials.gov/study/NCT05710328)
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT ID: NCT03488693 (https://clinicaltrials.gov/study/NCT03488693)
Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer
NCT ID: NCT05183828 (https://clinicaltrials.gov/study/NCT05183828)
Study of DF1001 in Patients with Advanced Solid Tumors
NCT ID: NCT04143711 (https://clinicaltrials.gov/study/NCT04143711)
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
NCT ID: NCT00353483 (https://clinicaltrials.gov/study/NCT00353483)
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT ID: NCT03643861 (https://clinicaltrials.gov/study/NCT03643861)
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
NCT ID: NCT01000883 (https://clinicaltrials.gov/study/NCT01000883)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://clinicaltrials.gov/study/NCT04704661)
Remotely Delivered, Culturally Tailored Weight Loss Interventions Among Latina Breast Cancer Survivors
NCT ID: NCT05930483 (https://clinicaltrials.gov/study/NCT05930483)
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
NCT ID: NCT06110793 (https://clinicaltrials.gov/study/NCT06110793)
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
NCT ID: NCT05746897 (https://clinicaltrials.gov/study/NCT05746897)
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy
NCT ID: NCT06185205 (https://clinicaltrials.gov/study/NCT06185205)
A Low-Insulinemic Dietary Intervention to Reduce Breast Cancer Risk in High-Risk Women
NCT ID: NCT06635005 (https://clinicaltrials.gov/study/NCT06635005)
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery
NCT ID: NCT04815083 (https://clinicaltrials.gov/study/NCT04815083)
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
NCT ID: NCT06763328 (https://clinicaltrials.gov/study/NCT06763328)
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
NCT ID: NCT06120283 (https://clinicaltrials.gov/study/NCT06120283)
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
NCT ID: NCT04468061 (https://clinicaltrials.gov/study/NCT04468061)
SRG-514 Administered Intraoperatively to Patients Undergoing Breast-conserving Cancer Surgery
NCT ID: NCT06300411 (https://clinicaltrials.gov/study/NCT06300411)
Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)
NCT ID: NCT06902311 (https://clinicaltrials.gov/study/NCT06902311)
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy
NCT ID: NCT04454528 (https://clinicaltrials.gov/study/NCT04454528)
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
NCT ID: NCT05296798 (https://clinicaltrials.gov/study/NCT05296798)
A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer
NCT ID: NCT05989828 (https://clinicaltrials.gov/study/NCT05989828)
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
NCT ID: NCT04569747 (https://clinicaltrials.gov/study/NCT04569747)
RAPA-201 Therapy of Solid Tumors
NCT ID: NCT05144698 (https://clinicaltrials.gov/study/NCT05144698)
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease
NCT ID: NCT04588545 (https://clinicaltrials.gov/study/NCT04588545)
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
NCT ID: NCT05256745 (https://clinicaltrials.gov/study/NCT05256745)
Identifying and Caring for Individuals With Inherited Cancer Syndrome
NCT ID: NCT04494945 (https://clinicaltrials.gov/study/NCT04494945)
Study to Evaluate Biomarkers and Safety of Dapagliflozin Concomitant with Neoadjuvant Therapy
NCT ID: NCT05989347 (https://clinicaltrials.gov/study/NCT05989347)
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
NCT ID: NCT06075953 (https://clinicaltrials.gov/study/NCT06075953)
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT ID: NCT06058377 (https://clinicaltrials.gov/study/NCT06058377)
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
NCT ID: NCT04638751 (https://clinicaltrials.gov/study/NCT04638751)
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT ID: NCT04852887 (https://clinicaltrials.gov/study/NCT04852887)
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
NCT ID: NCT03463954 (https://clinicaltrials.gov/study/NCT03463954)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.